PGEN Valuation

Precigen Inc

Add to Watchlist

Advanced Chart

4.750

-0.01(-0.210%)1D

Overview
Forecast
Valuation
Earnings

PGEN Relative Valuation

PGEN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PGEN is overvalued; if below, it's undervalued.

Historical Valuation

Precigen Inc (PGEN) is now in the Fair zone, suggesting that its current forward PS ratio of 18.87 is considered Fairly compared with the five-year average of -5.63. The fair price of Precigen Inc (PGEN) is between 4.49 to 18.03 according to relative valuation methord.

Relative Value

Fair Zone

4.49-18.03

Current Price：4.76

Fair

-25.00

Trailing

Forward

0.00

EV/EBITDA

Precigen Inc. (PGEN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.01. The thresholds are as follows: Strongly Undervalued below -9.85, Undervalued between -9.85 and -5.43, Fairly Valued between 3.40 and -5.43, Overvalued between 3.40 and 7.82, and Strongly Overvalued above 7.82. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-27.75

EV/EBIT

Precigen Inc. (PGEN) has a current EV/EBIT of -27.75. The 5-year average EV/EBIT is -7.17. The thresholds are as follows: Strongly Undervalued below -18.28, Undervalued between -18.28 and -12.72, Fairly Valued between -1.62 and -12.72, Overvalued between -1.62 and 3.94, and Strongly Overvalued above 3.94. The current Forward EV/EBIT of -27.75 falls within the Strongly Undervalued range.

19.91

Precigen Inc. (PGEN) has a current PS of 19.91. The 5-year average PS is 34.23. The thresholds are as follows: Strongly Undervalued below -32.81, Undervalued between -32.81 and 0.71, Fairly Valued between 67.76 and 0.71, Overvalued between 67.76 and 101.28, and Strongly Overvalued above 101.28. The current Forward PS of 19.91 falls within the Historic Trend Line -Fairly Valued range.

-20.56

P/OCF

Precigen Inc. (PGEN) has a current P/OCF of -20.56. The 5-year average P/OCF is -8.37. The thresholds are as follows: Strongly Undervalued below -18.62, Undervalued between -18.62 and -13.49, Fairly Valued between -3.24 and -13.49, Overvalued between -3.24 and 1.89, and Strongly Overvalued above 1.89. The current Forward P/OCF of -20.56 falls within the Strongly Undervalued range.

-20.49

P/FCF

Precigen Inc. (PGEN) has a current P/FCF of -20.49. The 5-year average P/FCF is -7.20. The thresholds are as follows: Strongly Undervalued below -19.25, Undervalued between -19.25 and -13.22, Fairly Valued between -1.17 and -13.22, Overvalued between -1.17 and 4.85, and Strongly Overvalued above 4.85. The current Forward P/FCF of -20.49 falls within the Strongly Undervalued range.

Precigen Inc (PGEN) has a current Price-to-Book (P/B) ratio of -38.55. Compared to its 3-year average P/B ratio of 0.85 , the current P/B ratio is approximately -4617.54% higher. Relative to its 5-year average P/B ratio of 4.78, the current P/B ratio is about -907.01% higher. Precigen Inc (PGEN) has a Forward Free Cash Flow (FCF) yield of approximately -5.19%. Compared to its 3-year average FCF yield of -21.02%, the current FCF yield is approximately -75.30% lower. Relative to its 5-year average FCF yield of -16.73% , the current FCF yield is about -68.96% lower.

-38.47

P/B

Median3y

0.85

Median5y

4.78

-4.92

FCF Yield

Median3y

-21.02

Median5y

-16.73

Competitors Valuation Multiple

The average P/S ratio for PGEN's competitors is 63.70, providing a benchmark for relative valuation. Precigen Inc Corp (PGEN) exhibits a P/S ratio of 19.91, which is -68.74% above the industry average. Given its robust revenue growth of 19.39%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Janux Therapeutics Inc

Vera Therapeutics Inc

Loss

1.47B

SNDX.O

Syndax Pharmaceuticals Inc

Xeris Biopharma Holdings Inc

4.01

48.84%

1.27B

Performance Decomposition

Market capitalization of PGEN increased by 401.05% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.03 to -11.06.

The secondary factor is the Revenue Growth, contributed 19.39%to the performance.

Overall, the performance of PGEN in the past 1 year is driven by P/E Change. Which is more unsustainable.

19.39%

717.00K → 856.00K

Revenue Growth

-62.04%

-8.20K → -3.11K

Margin Expansion

443.70%

-2.03 → -11.06

P/E Change

401.05%